文献速递骨软组织肉瘤与黑色素瘤

儿童TRK融合肉瘤及相关间叶肿瘤患者中拉罗替尼的可选择停药

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
PubMed 文献 · J Clin Oncol · 2025-01-27

该分析纳入两项临床试验中91例18岁以下TRK融合肉瘤患者,评估拉罗替尼疗效安全性及选择停药后观察等待策略。总缓解率87%(95%CI 78-93),47例停药,16例进展后全部恢复用药,15例(94%)获疾病控制。拉罗替尼在儿童TRK融合肉瘤中显示持久缓解和良好安全性,选择患者停药可行。

要点

  • 拉罗替尼治疗儿童TRK融合肉瘤总缓解率87%(95%CI 78-93)。
  • 47例选择停药观察,16例进展后全部恢复拉罗替尼,15例(94%)获疾病控制。
  • 治疗相关不良事件最高为1级或2级者各占25%。

核心结论

  • 拉罗替尼在儿童TRK融合肉瘤中持续显示持久缓解和良好安全性。
  • 在获得客观缓解的选择性患者中停药可行,选择停药后进展者恢复治疗可见临床获益。

研究设计与样本

  • 基于两项临床试验的方案定义观察等待子集分析,纳入91例18岁以下患者,其中婴儿纤维肉瘤49例、其他软组织肉瘤或相关间叶肿瘤41例、骨肉瘤1例。
  • 观察等待期间如疾病进展允许恢复拉罗替尼治疗。

主要发现

  • 治疗相关不良事件最高为1级者占25%,最高为2级者占25%。
  • 总缓解率为87%(95%CI 78-93)。
  • 观察等待分析中47例停用拉罗替尼,从停药至疾病进展的中位时间未达到。
  • 观察等待期间16例出现肿瘤进展,全部16例恢复拉罗替尼治疗,15例(94%)达到疾病控制,其中11例客观缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a protocol-defined wait-and-see subset analysis of eligible patients where treatment resumption with larotrectinib was allowed if disease progressed. We also assessed the safety and efficacy of larotrectinib in all pediatric patients with sarcoma. This cohort included 91 patients (younger than 18 years) from two clinical trials: infantile fibrosarcoma (49), other soft tissue sarcomas or related mesenchymal tumors (41), and bone sarcoma (1). Treatment-related adverse events were of maximum grade 1 or 2 in 25% and 25% of patients, respectively. The overall response rate was 87% (95% CI, 78 to 93). In the wait-and-see analysis, 47 patients discontinued larotrectinib. Median time from discontinuation to disease progression was not reached. Sixteen patients had tumor progression during the wait-and-see period. All 16 patients resumed larotrectinib, and 15 (94%) achieved disease control, with 11 objective responses. Larotrectinib continues to demonstrate durable responses with favorable safety in children with TRK fusion sarcomas. Treatment discontinuation is feasible in select patients with objective response and clinical benefit noted in those who have disease progression after elective treatment discontinuation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mascarenhas L, DuBois SG, Albert CM, et al. Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. J Clin Oncol. 2025. PMID: 39869835. doi:10.1200/JCO.24.00848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。